Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01771822 · ClinicalTrials.gov registry record · Phase 1

Ibuprofen 5% Topical Gel CIPT

A Phase 1 study of Pain, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT01771822 is a Phase 1 study of Pain that has completed, run by Pfizer. The registered enrollment target is 50 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01771822, a Phase 1 study of Pain, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This study will determine the potential of Ibuprofen 5% Topical Gel and its vehicle gel to cause irritation after repeated topical application to the healthy skin of human subjects under controlled conditions.

Conditions Studied

Interventions

  • DRUG Ibuprofen 5% topical gel
  • DRUG Topical gel vehicle
  • DRUG Sodium lauryl sulfate 0.2%
  • DRUG Sodium chloride solution 0.9% (saline)

Study Locations (1)

New Jersey

  • Pfizer Investigational Site - Carlstadt

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2013-01
Est. Completion 2013-02
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01771822

The ClinicalTrials.gov registry entry for NCT01771822 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (84% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 4 interventions - of which Ibuprofen 5% topical gel is the first listed.

NCT01771822 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT01771822 about?

NCT01771822 is a clinical study titled "Ibuprofen 5% Topical Gel CIPT". This study will determine the potential of Ibuprofen 5% Topical Gel and its vehicle gel to cause irritation after repeated topical application to the healthy skin of human subjects under controlled conditions.

What is the current status of trial NCT01771822?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2013-01. Estimated completion is 2013-02.

What conditions does trial NCT01771822 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT01771822?

The interventions under investigation include: Ibuprofen 5% topical gel (DRUG), Topical gel vehicle (DRUG), Sodium lauryl sulfate 0.2% (DRUG), Sodium chloride solution 0.9% (saline) (DRUG).

Who is sponsoring clinical trial NCT01771822?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01771822 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.